Trevena (NASDAQ:TRVN) Stock Passes Below Two Hundred Day Moving Average of $1.23

Trevena, Inc. (NASDAQ:TRVN – Get Rating) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.23 and traded as low as $0.98. Trevena shares last traded at $1.01, with a volume of 71,197 shares.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on shares of Trevena in a report on Tuesday, January 10th. They set a “sell” rating for the company.

Trevena Trading Up 2.2 %

The company has a debt-to-equity ratio of 0.61, a quick ratio of 4.51 and a current ratio of 4.60. The firm has a 50-day moving average of $1.50 and a 200-day moving average of $1.23. The firm has a market capitalization of $7.02 million, a P/E ratio of -0.11 and a beta of 2.10.

Hedge Funds Weigh In On Trevena

A number of institutional investors have recently added to or reduced their stakes in TRVN. Jane Street Group LLC purchased a new stake in Trevena during the 2nd quarter valued at $25,000. Dimensional Fund Advisors LP bought a new position in shares of Trevena in the fourth quarter worth about $40,000. Virtu Financial LLC increased its holdings in shares of Trevena by 72.7% in the third quarter. Virtu Financial LLC now owns 290,480 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 122,242 shares during the last quarter. Russell Investments Group Ltd. bought a new position in shares of Trevena during the 2nd quarter valued at approximately $51,000. Finally, Captrust Financial Advisors grew its position in Trevena by 10,526.3% in the first quarter. Captrust Financial Advisors now owns 201,900 shares of the biopharmaceutical company’s stock worth $111,000 after acquiring an additional 200,000 shares in the last quarter.

About Trevena

(Get Rating)

Trevena, Inc engages in the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A.